• 울산대학교 의학박사
• 한양대학교 의학석사
• 한양대학교 의학사

• 2017-2025  | 가천대 길병원 교수
• 2016-2017  | 울산대학교병원 교수
• 2009-2016  | 울산대학교병원 부교수
• 2008-2009  | M. D. Anderson Cancer Center 교환교수
• 2004-2008  | 울산대학교병원 조교수
• 2003-2004  | 서울아산병원 종양혈액내과 전임의
• 1996-2000  | 한양대학교병원 내과 전공의 수료

• 2011 | 대한교혈모세포이식학회 최우수연제상
• 2007 | 대한혈액학회 우수연제상

• 2024-현재  | Asian Bone Marrow Failure Syndrome Symposium 학술이사
• 2025-현재  | 혈액지지학회 홍보이사
• 2019-현재  | 대한혈액학회 만성골수성백혈병 연구회 위원장
• 2017-2019  | 대한혈액학회 AML/MDS 연구회 운영위원
• 2016-2022  | 대한혈액학회 재생불량빈혈 연구회 운영위원
• 2011-2012  | 대한혈액학회 사회봉사교육위원
• 2011-2013  | 대한조혈모세포이식학회 학술위원

•  Upfront vs delayed allogeneic HCT for aplastic anemia >40 years.  (Submitted). 2025. 
•  Deep learning approaches to predict treatment-free remission in CML.  PLoS One (Submitted). 2025. 
•  Gaucher Earlier Diagnosis Consensus Point-Scoring System for children & young adults: retrospective + prospective evaluation in Korea.  (Submitted). 2025. 
•  Understanding disease management and the patient journey in CML: CML SUN Survey (South Korea).  (Submitted). 2025. 
•  Gene expression analysis of patients with CML who discontinued TKI.  Ann Hematol. 2025. 
•  Diagnosis and treatment of transfusion-related iron overload.  J Korean Med Assoc. 2022. 
•  Lenalidomide for anemia correction in lower-risk del(5q) MDS (Asian ethnicity).  Blood Res. 2021. 
•  Ultra-deep sequencing of BCR-ABL1 kinase domain in newly diagnosed CML.  Leuk Res. 2021. 
•  Early dasatinib dose reduction does not compromise outcomes in CML: comparative analysis of two prospective trials.  Leuk Res. 2024. 
•  Auto-HCT after high-dose cytarabine consolidation for CBF-AML CR1: phase II.  Int J Hematol. 2021. 
•  Treatment-free remission of CML in real-world practice by MR4.3.  Leuk Res. 2021. 
•  Real-world management of CML in South Korea: TARGET survey.  Blood Res. 2021. 
•  Age and remission induction therapy for AML: Korean AML registry.  PLoS One. 2021. 
•  Outcomes of decitabine for newly diagnosed AML in older adults and role of MNA-SF.  PLoS One. 2020. 
•  Long-term data: radotinib vs imatinib in newly diagnosed CP-CML (RERISE).  Br J Haematol. 2020. 
•  Prospective randomized trial comparing two doses of rabbit ATG in severe AA (APBMT).  Br J Haematol. 2019. 
•  Lenalidomide as second-line after HMA failure in MDS.  Br J Haematol. 2019. 
•  Effect of stem cell source and dose on allogeneic HCT in adult idiopathic AA (Korean trials).  Acta Haematol. 2019. 
•  Derived neutrophil-to-lymphocyte ratio is an independent prognostic factor in transplant-ineligible MM.  Acta Haematol. 2018. 
•  ENESTKorea: phase 4 nilotinib in CP-CML (Korean cohort).  Cancer Med. 2018. 
•  Frequency/sensitivity of BCR-ABL1 kinase domain mutations in Asian vs Caucasian imatinib-resistant CP-CML.  Clin Lymphoma Myeloma Leuk. 2018. 
•  Eculizumab in PNH with or without aplastic anemia: prospective Korean cohort.  Blood Res. 2017. 
•  Prospective randomized comparison of idarubicin vs high-dose daunorubicin in induction for newly diagnosed AML.  J Clin Oncol. 2017. 
•  Benefits of hypomethylating therapy in IPSS lower-risk MDS: retrospective multicenter case series.  Leuk Res. 2017. 
•  Targeting c-KIT (CD117) by dasatinib and radotinib promotes AML cell death.  Sci Rep. 2017. 
•  Radotinib induces high cytotoxicity in c-KIT+ AML cells.  Eur J Pharmacol. 2017. 
•  Trend and treatment patterns of AA, PRCA, MDS in Korea: nationwide analysis.  Int J Hematol. 2017. 
•  RIC with busulfan, fludarabine, ATG for HCT from unrelated/haplo donors in AML in remission.  Biol Blood Marrow Transplant. 2017. 
•  VMP (bortezomib-melphalan-prednisone) as initial therapy in auto-SCT-ineligible MM: multicenter observational.  Oncotarget. 2017. 
•  Radotinib vs imatinib in newly diagnosed CP-CML: 12-month results (RERISE).  Clin Cancer Res. 2017. 
•  Outcomes of hypomethylating therapy: prognostic value of IPSS-R in lower-risk MDS.  Ann Hematol. 2016. 
•  LIGHT (TNFSF14) increases survival and proliferation of human BM-MSCs via LTβR.  PLoS One. 2016. 
•  PD-1 and PD-L1 expression in extranodal NK/T-cell lymphoma, nasal type.  Ann Hematol. 2016. 
•  BK virus encephalitis with thrombotic microangiopathy after allogeneic HSCT.  Transplant Infect Dis. 2016. 
•  Angioimmunoblastic T-cell lymphoma in a patient with Klinefelter syndrome.  Am J Case Rep. 2016. 
•  Coexistence of follicular lymphoma and unclassifiable MPN in a treatment-naïve patient: case report.  Oncology Lett. 2016. 
•  Comparable allogeneic HCT outcome of haplo-identical family donor vs alternative donor in adult aplastic anemia.  Acta Haematol. 2016. 
•  Radotinib inhibits proliferation, induces apoptosis and G1 arrest via CDKI–CDK–cyclin regulation in AML cells.  Eur J Pharmacol. 2016. 
•  Biweekly dose-dense GEMOX + dexamethasone for R/R aggressive NHL: phase II.  Asia Pac J Clin Oncol. 2016. 
•  Prognostic factors for re-mobilization with plerixafor + G-CSF after prior mobilization failure (lymphoma/MM).  Ann Hematol. 2016. 
•  Peripheral T-cell lymphomas in elderly: HASEK retrospective analysis.  Ann Hematol. 2016. 
•  Continuous-infusion FLAG for ≥60-yr resistant AML: phase II vs younger-patients trial.  Eur J Haematol. 2016. 
•  Long-term follow-up of imatinib + combination chemo in newly diagnosed Ph+ ALL.  Am J Hematol. 2015. 
•  Nilotinib + multiagent chemo for newly diagnosed Ph+ ALL adults: phase II.  Blood. 2015. 
•  Radotinib induces apoptosis of CD11b+ cells differentiated from AML.  PLoS One. 2015. 
•  Incidence/prognostic impact of c-KIT, WT1, CEBPA, CBL and epigenetic mutations in CBF-AML (Korean multicenter).  Ann Lab Med. 2015. 
•  Deferasirox efficacy/safety via ferritin & labile plasma iron in AA, MDS, AML with transfusional iron overload.  Transfusion. 2015. 
•  Adjuvant chemotherapy for elderly gastric cancer after D2 gastrectomy: single-center Korea.  Asia Pac J Clin Oncol. 2015. 
•  Efficacy of H. pylori eradication as 1st-line for ITP with moderate thrombocytopenia.  Ann Hematol. 2015. 
•  Azacitidine pretreatment followed by non-myeloablative SCT in higher-risk MDS.  Acta Haematol. 2015. 
•  Rosmarinic acid potentiates ATRA-induced macrophage differentiation in NB4 APL cells.  Eur J Pharmacol. 2015. 
•  Phase II of IMEP (ifosfamide/methotrexate/etoposide/prednisolone) for stage I–II ENKTL, nasal type.  Oncologist. 2014. 
•  Prognostic model of therapy-related MDS for survival and AML transformation.  Clin Lymphoma Myeloma Leuk. 2014. 
•  Dasatinib accelerates VPA-induced AML cell death by regulating differentiation capacity.  PLoS One. 2014. 
•  Efficacy and safety of radotinib in CP-CML resistant/intolerant to TKIs.  Haematologica. 2014. 
•  Chromosome 13 deletion and hypodiploidy are robust prognostic factors in Korean MM: web-based registry.  Ann Hematol. 2014. 
•  Relationship between success of empirical IV itraconazole and clinical parameters in immunocompromised patients on oral prophylaxis.  Ann Hematol. 2014. 
•  Allogeneic HCT without TBI from unrelated donors in adult idiopathic aplastic anemia: Flu vs Cy-ATG.  Leuk Res. 2014. 
•  Busulfan-containing conditioning is optimal for auto-SCT in DLBCL.  Leuk Lymphoma. 2014. 
•  Cytogenetic classification in Korean MM: significance of hyperdiploidy (47–50) and number of structural abnormalities.  Eur J Haematol. 2014. 
•  Reduced-dose idarubicin + FLAG for resistant AML <65: phase II vs higher-dose trial.  Acta Haematol. 2014. 
•  Outcomes and prognostic factors of empirical antifungal therapy with itraconazole in hematologic malignancies.  Yonsei Med. 2014. 
•  Outcome of R-CHOP in DLBCL with bone marrow involvement.  Cancer Res Treat. 2013. 
•  Genome-wide genotype-based risk model for survival in NK-AML.  Br J Haematol. 2013. 
•  Hepatic sinusoidal obstruction syndrome after allogeneic HCT in adult idiopathic aplastic anemia.  Leuk Res. 2013. 
•  Escalated daunorubicin as induction for Ph-negative adult ALL.  Ann Hematol. 2013. 
•  Predictive factors for successful imatinib cessation in CML.  Am J Hematol. 2013. 
•  Inclusion of hemoglobin level in prognostic score improves stratification in APL.  Int J Hematol. 2013. 
•  SNP array-based karyotyping in MDS and CMML and impact on outcomes after decitabine.  Ann Hematol. 2013. 
•  Successful erythropoietin therapy after alemtuzumab and cyclosporin A for epoetin-induced PRCA.  Korean J Med. 2013. 
•  Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) for elderly AML.  Am J Hematol. 2013. 
•  Randomized trial comparing BuCy vs BuFlu as myeloablative conditioning.  J Clin Oncol. 2013. 
•  KIT D816 mutation associates with adverse outcomes in core binding factor AML, especially with RUNX1/RUNX1T1.  Ann Hematol. 2013. 
•  A genome-wide SNP array can improve prognostic stratification of core binding factor AML.  Am J Hematol. 2012. 
•  Clinical features and outcomes of Hodgkin’s lymphoma in Korea: CISL.  Ann Hematol. 2012. 
•  Arsenic trioxide induces depolymerization of microtubules in an APL cell line.  Korean J Hematol. 2012. 
•  Gemcitabine + UFT as first-line treatment in elderly advanced NSCLC: phase II.  Lung Cancer. 2012. 
•  Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group.  Leuk Lymphoma. 2012. 
•  Allogeneic hematopoietic stem cell transplantation for adults >40 years with acquired aplastic anemia.  Biol Blood Marrow Transplant. 2012. 
•  A randomized comparison of cyclophosphamide versus reduced cyclophosphamide plus fludarabine for allogeneic HCT in aplastic anemia and hypoplastic MDS.  Ann Hematol. 2012. 
•  A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.  Blood. 2011. 
•  Adverse prognostic impact of abnormal lesions detected by genome-wide SNP-array karyotyping in AML with normal karyotype.  J Clin Oncol. 2011. 
•  Clinical effect of reduced-intensity conditioning regimen containing anti-thymocyte globulin for hematopoietic cell transplantation from unrelated donors.  Am J Hematol. 2011. 
•  Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.  Leuk Lymphoma. 2011. 
•  Comparison Between Matched Related and Alternative Donors of Allogeneic Hematopoietic Stem Cells Transplanted into Adult Patients with Acquired Aplastic Anemia: Multivariate and Propensity Score-Matched Analysis.  Biol Blood Marrow Transplant. 2011. 
•  Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.  Ann Hematol. 2011. 
•  Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.  Haematologica. 2010. 
•  Gefitinib enhances arsenic trioxide (As2O3)-induced differentiation of acute promyelocytic leukemia cell line.  Leuk Res. 2010. 
•  Clinical Features and Survival Outcomes in Patients with Multiple Myeloma: Analysis of Web-Based Data from the Korean Myeloma Registry.  Acta Haematol. 2009. 
•  Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: A prospective, multicenter phase II study.  Am J Hematol. 2009. 
•  Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.  Thromb Haemost. 2009. 
•  Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell Lymphoma, Unspecified: Complete Remission at Transplantation and the Prognostic Index of Peripheral T Cell Lymphoma Are the Major Factors Predictive of Outcome.  Biol Blood Marrow Transplant. 2009. 
•  Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront Single Autologous Transplantation.  Biol Blood Marrow Transplant. 2009. 
•  A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.  Leukemia Research. 2009. 
•  Management of Myelodysplastic Syndromes: Just the Beginning.  ONCOLOGY. 2008. 
•  Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.  Cancer Chemother Pharmacol. 2008. 
•  Prospective phase II trial of a combined with fixed dose rate infusion of gemcitabine, cisplatin and UFT as a first-line treatment in patients with advanced non-small cell lung carcinoma.  Lung Cancer. 2008. 
•  Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.  Clinical Lymphoma and Myeloma. 2008. 
•  Enhanced bacteriocidal function by WKYMVm in patients with acute leukemia.  Leuk Res. 2008. 
•  Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: A phase II study.  Chemotherapy. 2008. 
•  Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient.  Korean J Intern Med. 2006. 
•  Disseminated extranodal marginal zone B-cell lymphoma as a isolated pulmonary nodule.  Tuberculosis and Respirtory Diseases. 2006. 
•  New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy.  Biol Blood Marrow Transplant. 2006. 
•  Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma.  Bone Marrow Transplant. 2006. 
•  Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia.  Ann Hematol. 2006. 
•  Granulocyte function is stimulated by a novel hexapeptide, WKYMVm, in chemotherapy-treated cancer patients.  Exp Hematol. 2006. 
•  Risk score model for fatal intracranial hemorrhage in acute leukemia.  Leukemia. 2006. 
•  A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment.  Jpn J Clin Oncol. 2005. 
•  Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.  J Korean Med Sci. 2005. 
•  Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma.  Bone Marrow Transplant. 2004. 
•  Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients.  Haematologica. 2004. 
•  Eosinophilic fasciitis preceding relapse of peripheral T-cell lymphoma.  J Korean Med Sci. 2000. 
•  Detection of micrometastasis of stomach cancer using PCR in peripheral blood.  Cancer Research and Treatment. 2000. 
•  p53 protein expression and its prognostic importance in patients with nodal non-Hodgkin's lymphoma.  J Korean Med Sci. 2000. 
•  Clinical application of autologous hematopoietic stem cell transplantation.  Hanyang Med J. 1999. 
•  Isolated Elevation of aspartate aminotransferase by mactoenzyme formation.  Kor J Hepatol. 1999. 
•  Epstein Barr virus associated hemophagocytic syndrome.  J Korean Med Sci. 1997. 

• [라포르시안] "만성골수성백혈병 환자 미충족 수요 반영한 치료 목표 수립 필요" 2026-04-02